Apollo Medical Holdings, Inc. (OTCMKTS:AMEH) CEO Warren Hosseinion sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, November 23rd. The stock was sold at an average price of $16.55, for a total value of $827,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Warren Hosseinion also recently made the following trade(s):
- On Tuesday, November 20th, Warren Hosseinion sold 40,000 shares of Apollo Medical stock. The stock was sold at an average price of $18.28, for a total value of $731,200.00.
- On Thursday, August 30th, Warren Hosseinion sold 22,900 shares of Apollo Medical stock. The stock was sold at an average price of $15.94, for a total value of $365,026.00.
- On Tuesday, August 28th, Warren Hosseinion sold 30,000 shares of Apollo Medical stock. The stock was sold at an average price of $17.00, for a total value of $510,000.00.
Shares of AMEH traded up $0.74 during trading on Monday, reaching $18.12. The company’s stock had a trading volume of 83,500 shares, compared to its average volume of 80,204. Apollo Medical Holdings, Inc. has a twelve month low of $7.95 and a twelve month high of $30.00.
Apollo Medical (OTCMKTS:AMEH) last announced its earnings results on Wednesday, November 14th. The healthcare company reported $0.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.15. The business had revenue of $167.28 million during the quarter.
Several institutional investors and hedge funds have recently made changes to their positions in AMEH. BlackRock Inc. acquired a new position in shares of Apollo Medical in the 2nd quarter valued at approximately $28,267,000. Vanguard Group Inc. raised its position in shares of Apollo Medical by 184.8% in the 3rd quarter. Vanguard Group Inc. now owns 928,911 shares of the healthcare company’s stock valued at $20,501,000 after purchasing an additional 602,710 shares in the last quarter. Northern Trust Corp acquired a new position in shares of Apollo Medical in the 2nd quarter valued at approximately $6,137,000. Royce & Associates LP acquired a new position in shares of Apollo Medical in the 3rd quarter valued at approximately $1,898,000. Finally, Cadence Capital Management LLC acquired a new position in shares of Apollo Medical in the 3rd quarter valued at approximately $1,619,000.
Separately, Zacks Investment Research upgraded Apollo Medical from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Tuesday, November 20th.
Apollo Medical Company Profile
Apollo Medical Holdings, Inc is a patient-centered, physician-centric integrated population health management company working to provide coordinated, outcomes-based medical care. The Company operates in healthcare delivery segment. Its operations include Hospitalists, which include its contracted physicians focusing on the delivery of medical care to hospitalized patients; an accountable care organization (ACO), which focuses on providing care to Medicare fee-for-service patients; an independent practice association (IPA), which contracts with physicians and provides care to Medicare, Medicaid, commercial and dual-eligible patients on a risk- and value-based fee basis; approximately three clinics, which it owns or operates, and which provide specialty care in the greater Los Angeles area, and Palliative care, home health and hospice services, which include its at-home and end-of-life services.
Further Reading: Dividend
Receive News & Ratings for Apollo Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Medical and related companies with MarketBeat.com's FREE daily email newsletter.